ZyVersa Therapeutics and Larkspur Health Acquisition have entered into a definitive merger agreement that gives the combination an enterprise value of $108.9 million.
ZyVersa is a clinical stage specialty biopharmaceutical company developing product candidates that address unmet medical needs in the areas of renal and inflammatory diseases.
The deal calls for cash proceeds of approximately $77.67 million in Larkspur’s trust account (less any redemptions and the payment of expenses) and a $7 million PIPE anchored by new institutional investors.
If approved by the SPAC’s shareholders, the deal is expected to close in the fourth quarter. Shares would list on the Nasdaq under ticker symbol ZVSA. Read more.
